Demographic and HIV-specific characteristics of participants enrolled in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial

Author:

Sharma S1,Babiker AG2,Emery S3,Gordin FM4,Lundgren JD5,Neaton JN1,Bakowska E6,Schechter M7,Wiselka MJ8,Wolff MJ9,

Affiliation:

1. Division of Biostatistics; School of Public Health; University of Minnesota; Minneapolis MN USA

2. Medical Research Council (MRC) Clinical Trials Unit at University College London; London UK

3. The Kirby Institute; University of New South Wales; Sydney Australia

4. Washington DC Veterans Affairs Medical Center and George Washington University; Washington DC USA

5. Department of Infectious Diseases; Copenhagen HIV Programme, Rigshospitalet, University of Copenhagen; Copenhagen Denmark

6. Wojewodzki Szpital Zakazny; Warsaw Poland

7. Projeto Praça Onze; Universidade Federal do Rio de Janeiro; Rio de Janeiro Brazil

8. University Hospitals of Leicester NHS Trust; Leicester Royal Infirmary; Leicester UK

9. University of Chile School of Medicine, Fundacion Arriaran; Santiago Chile

Funder

National Institute of Allergy and Infectious Diseases

NIH Clinical Center

National Cancer Institute

National Heart, Lung, and Blood Institute

National Institute of Mental Health

National Institute of Neurological Disorders and Stroke

National Institute of Arthritis and Musculoskeletal Disorders

French Agence Nationale de Recherches sur le SIDA et les Hépatites Virales (ANRS)

German Ministry of Education and Research

European AIDS Treatment Network (NEAT)

Australian National Health and Medical Research Council

UK Medical Research Council

National Institute for Heath Research

Publisher

Wiley

Subject

Pharmacology (medical),Infectious Diseases,Health Policy

Reference22 articles.

1. Zidovudine in persons with asymptomatic HIV infection and CD4 cell counts greater than 400 per cubic millimeter;Cooper;N Engl J Med,1993

2. Concorde: MRC/ANRS randomized double blind controlled trial or immediate and deferred zidovudine in symptom-free HIV infection;Concorde Coordinating Committee;Lancet,1994

3. A comparison of immediate with deferred zidovudine therapy for asymptomatic HIV-infected adults with CD4 cell counts of 500 or more per cubic millimeter;Volberding;N Engl J Med,1995

4. Joint United Nations Programme on HIV/AIDS (UNAIDS) Global Report 2013 2013

5. Joint United Nations Programme on HIV/AIDS (UNAIDS) Global Report 2010 2010

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3